Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Tomelleri

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
Frontiers in Immunology|May 17, 2021
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-InflammationEmanuel Della-Torre, Marco Lanzillotta, Corrado Campochiaro, et al.
European Journal of Internal Medicine|June 3, 2020
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort studyCorrado Campochiaro, Emanuel Della-Torre, Giulio Cavalli, et al.
Heart Failure Clinics|June 12, 2025
Positron Emission Tomography Imaging in VasculitisKornelis S M van der Geest, Berend G C Slijkhuis, Alessandro Tomelleri, et al.
Cardiology Clinics|April 1, 2023
Positron Emission Tomography Imaging in VasculitisKornelis S M van der Geest, Berend G C Slijkhuis, Alessandro Tomelleri, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 18, 2023
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilationAndrea Mastrangelo, Roberta Monardo, Laura Galli, et al.
The Lancet. Rheumatology|March 3, 2021
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort studyGiulio Cavalli, Alessandro Larcher, Alessandro Tomelleri, et al.
Journal of Neurology|September 19, 2023
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAF<sup>V600E</sup> mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman diseaseValentina Pieri, Giulia Berzero, Rosina Paterra, et al.
RMD Open|February 11, 2026
Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experienceArsène Mekinian, Sarah Meneses, Lucie Biard, et al.
Journal of Clinical Immunology|January 17, 2024
Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting TherapiesMarie-Christin Hoffmann, Giulio Cavalli, Natalie Fadle, et al.
The Lancet. Rheumatology|August 25, 2020
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort studyGiacomo De Luca, Giulio Cavalli, Corrado Campochiaro, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
Frontiers in Immunology|May 17, 2021
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-InflammationEmanuel Della-Torre, Marco Lanzillotta, Corrado Campochiaro, et al.
European Journal of Internal Medicine|June 3, 2020
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort studyCorrado Campochiaro, Emanuel Della-Torre, Giulio Cavalli, et al.
Heart Failure Clinics|June 12, 2025
Positron Emission Tomography Imaging in VasculitisKornelis S M van der Geest, Berend G C Slijkhuis, Alessandro Tomelleri, et al.
Cardiology Clinics|April 1, 2023
Positron Emission Tomography Imaging in VasculitisKornelis S M van der Geest, Berend G C Slijkhuis, Alessandro Tomelleri, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 18, 2023
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilationAndrea Mastrangelo, Roberta Monardo, Laura Galli, et al.
The Lancet. Rheumatology|March 3, 2021
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort studyGiulio Cavalli, Alessandro Larcher, Alessandro Tomelleri, et al.
Journal of Neurology|September 19, 2023
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAF<sup>V600E</sup> mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman diseaseValentina Pieri, Giulia Berzero, Rosina Paterra, et al.
RMD Open|February 11, 2026
Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experienceArsène Mekinian, Sarah Meneses, Lucie Biard, et al.
Journal of Clinical Immunology|January 17, 2024
Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting TherapiesMarie-Christin Hoffmann, Giulio Cavalli, Natalie Fadle, et al.
The Lancet. Rheumatology|August 25, 2020
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort studyGiacomo De Luca, Giulio Cavalli, Corrado Campochiaro, et al.
Pageof 13